How-Health-Systems-Are-Preparing-for-the-CAR-T-Surge

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawOnce reserved for small cohorts of patients with relapsed or refractory blood cancers, chimeric antigen receptor T-cell (CAR-T) therapy is now expanding rapidly, with multiple products approved across lymphomas, leukemias, and myeloma, and a robust pipeline targeting solid tumors. A recent review of the CAR-T landscape (Signal Transduct Target Ther 2025;10[1]:210) called it “the culmination of decades of